Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC
基因、环境和乳腺癌风险:Prof-SC 的 15 年随访
基本信息
- 批准号:8461709
- 负责人:
- 金额:$ 185.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2016-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAgeAlcohol consumptionAustraliaBRCA1 MutationBRCA1 geneBRCA2 MutationBRCA2 geneBehavior TherapyBody mass indexBreastCHEK2 geneCanadaCategoriesCharacteristicsClinicClinicalComplexCounselingDataDiagnosisDiseaseEnvironmentEpidemiologyExogenous Hormone TherapyFamilyFamily StudyFamily history ofFutureGenesGeneticGenetic Predisposition to DiseaseGenetic RiskGenetic VariationGenomicsGenotypeHereditary Breast CarcinomaHigh Risk WomanKnowledgeLactationMailsMalignant NeoplasmsMalignant neoplasm of ovaryMeasuresMedicalMedicineModelingMutationOvariectomyPhysical activityPredispositionPregnancyPreventionPrevention strategyPreventive screeningPublic HealthQuestionnairesRAD51C geneRadiationRecording of previous eventsRecruitment ActivityRelative (related person)Relative RisksReproductive HistoryResearchRiskRisk FactorsSamplingSelective Estrogen Receptor ModulatorsSingle Nucleotide PolymorphismSpecialistSurvivorsSusceptibility GeneTelephoneTest ResultTestingTimeUpdateVariantVital StatusWomanbasebreast cancer family registrycancer riskcigarette smokingclinical careclinical practicecohortdesignfollow-upgene discoverygenetic pedigreegenetic variantgenome wide association studyhigh riskimprovedmalignant breast neoplasmmodifiable riskmutation carriernon-geneticprospectivetreatment strategy
项目摘要
DESCRIPTION (provided by applicant): The discovery of BRCA1 and BRCA2 has resulted in more appropriate targeting of preventive and screening strategies for breast cancer. The on-going discovery of genes with moderate-risk mutations, and of multiple loci with common low-risk associated variants, means that more women at substantial genetic risk will be identified. Despite these advances in genomic medicine, there remain major unanswered questions for high risk women, the majority of whom do not carry mutations in any currently identified susceptibility genes: 1) What is my absolute risk of breast cancer?; 2) Are there modifiable factors that might lower my risk?; and, for women with prior breast cancer, 3) Can I do anything to lower my risk of a new cancer? Answers to these questions are fundamental to improving clinical care, and are long overdue. We lack answers to these important questions because many studies fail to capture the complexity of family history and lack long-term follow-up data to measure risk. Breast cancer risk prediction models commonly used at non-specialist clinics often capture risk based on only first-degree family history. No breast cancer prediction models have been based on, nor validated with, large prospective cohorts of high risk women. Studies that have examined potential modifiers of risk for BRCA1 and BRCA2 mutation carriers have used a retrospective design and included prevalent cancers over-sampled for disease survivors. To address these gaps, we propose to conduct active follow-up of 30,563 women of whom 2,597 are BRCA1 and BRCA2 mutation carriers. These women come from 9,739 families recruited and followed since 1995 in the U.S., Canada, and Australia. We collected the same extensive baseline epidemiologic, multigenerational pedigree, and genetic data for these women. Our prospective family study is enriched with women at increased susceptibility for breast cancer who vary widely in underlying Familial Risk Profile (FRP), which can be estimated using multigenerational pedigree and genetic data. We will estimate age-specific absolute, and relative, risks of breast cancer using two separate cohorts (18,530 women unaffected and 12,033 women affected at baseline), as a function of their estimated FRP, modifiable risk factors, and by BRCA1 and BRCA2 mutation status. By the end of follow-up, we estimate 1,427 of the women unaffected and 1,359 women affected at baseline will be diagnosed with a new breast cancer. 15-17% of these new cases will be in BRCA1 or BRCA2 mutation carriers. We will use our findings to enhance prediction models by incorporating information from multigenerational family history, measured gene variants, and risk factors. Clinical practice has been conservative in advising high risk women, particularly mutation carriers, about potential lifestyle modifications to reduce risk, basing this advice on studies of average-risk women. Instead, we propose to build more accurate prediction models for women across the spectrum of risk that can be used to tailor more effective prevention strategies.
描述(由申请人提供):BRCA1和BRCA2的发现使乳腺癌的预防和筛查策略更有针对性。正在进行的中等风险突变基因的发现,以及具有常见低风险相关变异的多个基因座的发现,意味着将发现更多具有重大遗传风险的妇女。尽管基因组医学取得了这些进步,但对于高危女性来说,仍然存在一些主要的未解之谜,她们中的大多数人没有携带任何目前确定的易感基因突变:1)我患乳腺癌的绝对风险是多少?2)是否存在可改变的因素可以降低我的风险?3)我能做些什么来降低我患新癌症的风险吗?这些问题的答案是改善临床护理的基础,也是人们期待已久的。我们缺乏这些重要问题的答案,因为许多研究未能捕捉到家族史的复杂性,也缺乏长期随访数据来衡量风险。非专科诊所通常使用的乳腺癌风险预测模型通常仅基于一级家族史来捕捉风险。目前还没有乳腺癌预测模型基于高风险女性的大规模前瞻性队列,也没有得到验证。研究检查了BRCA1和BRCA2突变携带者的潜在风险修饰因子,采用了回顾性设计,并包括对疾病幸存者进行的流行癌症过度采样。为了解决这些差距,我们建议对30,563名女性进行积极随访,其中2,597名女性是BRCA1和BRCA2突变携带者。这些妇女来自9,739个家庭,自1995年以来在美国、加拿大和澳大利亚被招募和跟踪。我们为这些妇女收集了同样广泛的基线流行病学、多代谱系和遗传数据。我们的前瞻性家庭研究丰富了乳腺癌易感性增加的女性,她们的潜在家族风险谱(FRP)差异很大,这可以通过多代谱系和遗传数据来估计。我们将使用两个单独的队列(18,530名未受影响的女性和12,033名基线时受影响的女性)来估计年龄特异性乳腺癌的绝对和相对风险,作为其估计的FRP,可改变的风险因素以及BRCA1和BRCA2突变状态的函数。在随访结束时,我们估计1,427名未受影响的妇女和1,359名基线时受影响的妇女将被诊断出患有新的乳腺癌。这些新病例中有15-17%是BRCA1或BRCA2突变携带者。我们将利用我们的发现,通过结合多代家族史、测量的基因变异和风险因素的信息来增强预测模型。临床实践在建议高风险妇女,特别是突变携带者,改变生活方式以降低风险方面一直是保守的,这一建议是基于对平均风险妇女的研究。相反,我们建议为女性建立更准确的预测模型,用于制定更有效的预防策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN L HOPPER其他文献
JOHN L HOPPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN L HOPPER', 18)}}的其他基金
Genome-wide association study of breast cancer in high-risk women
高危女性乳腺癌的全基因组关联研究
- 批准号:
8515365 - 财政年份:2012
- 资助金额:
$ 185.07万 - 项目类别:
Genome-wide association study of breast cancer in high-risk women
高危女性乳腺癌的全基因组关联研究
- 批准号:
8850827 - 财政年份:2012
- 资助金额:
$ 185.07万 - 项目类别:
Genome-wide association study of breast cancer in high-risk women
高危女性乳腺癌的全基因组关联研究
- 批准号:
8689753 - 财政年份:2012
- 资助金额:
$ 185.07万 - 项目类别:
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC (Diversity Supplement)
基因、环境和乳腺癌风险:Prof-SC(多样性补充)15 年随访
- 批准号:
8976660 - 财政年份:2011
- 资助金额:
$ 185.07万 - 项目类别:
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC
基因、环境和乳腺癌风险:Prof-SC 的 15 年随访
- 批准号:
8659352 - 财政年份:2011
- 资助金额:
$ 185.07万 - 项目类别:
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC
基因、环境和乳腺癌风险:Prof-SC 的 15 年随访
- 批准号:
8294606 - 财政年份:2011
- 资助金额:
$ 185.07万 - 项目类别:
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC
基因、环境和乳腺癌风险:Prof-SC 的 15 年随访
- 批准号:
8196169 - 财政年份:2011
- 资助金额:
$ 185.07万 - 项目类别:
AUSTRALASIAN COLORECTAL CANCER FAMILY REGISTRY
澳大利亚结直肠癌家族登记处
- 批准号:
6552988 - 财政年份:2002
- 资助金额:
$ 185.07万 - 项目类别:
AUSTRALASIAN COLORECTAL CANCER FAMILY REGISTRY
澳大利亚结直肠癌家族登记处
- 批准号:
6951166 - 财政年份:2002
- 资助金额:
$ 185.07万 - 项目类别:
AUSTRALASIAN COLORECTAL CANCER FAMILY REGISTRY
澳大利亚结直肠癌家族登记处
- 批准号:
6798340 - 财政年份:2002
- 资助金额:
$ 185.07万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 185.07万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 185.07万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 185.07万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 185.07万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 185.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 185.07万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 185.07万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 185.07万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 185.07万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 185.07万 - 项目类别:
Miscellaneous Programs